22 October 2024 – Said Darwazah, Hikma’s Executive Chairman, has received recognition for his contributions to healthcare, being named on the Arabian Business Healthcare Visionaries list [1] and ranked second on Forbes' Middle East Top 100 Healthcare Leaders, 2024 [2]. These recognitions reflect his decades of leadership at Hikma, and the company’s ongoing impact on the healthcare industry. 
 
Hikma, founded in Jordan over 45 years ago by Samih Darwazah, has grown into a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe. Our founder's legacy of making high-quality medicines accessible to those in need, continues to guide our purpose of putting better health within reach, every day. For over four decades, Said Darwazah has played a pivotal role in Hikma’s growth, working closely with a strong global leadership team and the Board, to ensure this purpose remains central to our strategy.  
 
Now, with 9,100 employees, Hikma reliably supplies vital, and often life-saving medications to patients and customers. This commitment drives our growth and enables us to address drug shortages in the US and Europe, while in MENA, where we've become the second-largest pharmaceutical company by sales [3], we provide essential medicines and improve access.  As Hikma expands, our purpose-driven approach allows us to have an increasingly positive impact on society through our three world-class business, Injectables, Branded, and Generics. 
 
Our three businesses create a diversified model that empowers us to improve healthcare outcomes in our key markets. Underpinning each business is our broad product portfolio, robust manufacturing, and commitment to quality. With 30 manufacturing plants across the US, MENA, and Europe, and more under construction, we further differentiate ourselves from our peers and deliver targeted solutions to meet regional needs while maintaining a global perspective on healthcare needs and innovation.  
 
These achievements would not be possible without our dedicated employees and strong global leadership team who ensure that we remain leaders in generic pharmaceuticals, delivering on our purpose.  

[1] https://www.arabianbusiness.com/powerlists/revealed-the-top-30-healthcare-visionaries-of-2024 

[2] https://www.forbesmiddleeast.com/lists/top-100-healthcare-leaders-2024/said-darwazah/

[3] Based on internal analysis by Hikma using IQVIA MIDAS® Monthly value sales data for Kuwait, KSA, UAE, Jordan, Lebanon, Egypt, Tunisia, Algeria and Morocco, MAT Dec 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.